bluuebunny/crossref_metadata_2025_split huggingface dataset:
Systemic and local antiinflammatory effect of magnesium chloride in experimental arthritis
Authors: Pinto Ana Carolina Matias Dinelly , de Melo Nunes Rodolfo , de Freitas Carvalho Waleska Vidal , Girão Virgínia Claudia Carneiro , Rocha Francisco Airton Castro 
Published: January 2024

Abstract
Objective
Despite some knowledge gaps in scientific evidence, MgCl2 is largely used for pain relief in musculoskeletal diseases. Mg salts were shown to provide analgesia postoperatively in orthopedic surgery and low Mg levels were linked to arthritis development and severity. We determined the anti-inflammatory activity of MgCl2 in an acute arthritis model.

Methods
Mice received 0.1 mg/25µL Zymosan (Zy) or saline into the knees. Joint pain was evaluated using von Frey test; cell influx, and interleukin (IL)-1 level were assessed in joint lavage at 6 h. Synovia were excised for histopathology and analysis of immunoexpression of nuclear factor kappa B (NFκB) and tumor necrosis factor (TNF)-α. Groups (n = 6/group) received either 90 mg/kg MgCl2/100 µL or saline per os (systemic) or 500 µg/25 µL MgCl2 or saline intra-articularly (i.a.) 30 min prior to Zy.

Results
MgCl2 given either systemically or locally significantly reduced cell influx (p = 0.0012 and p = 0.0269, respectively), pain (p = 0.0005 and p = 0.0038, respectively), and intra-articular IL-1 level (p = 0.0391), as compared to saline. Systemic MgCl2 significantly decreased NFκB (p < 0.05) immmunoexpression, as compared to saline.

Conclusion
MgCl2 given systemically or locally displayed anti-inflammatory activity in a severe acute arthritis model reducing cell influx, pain, and cytokine release. MgCl2 operates at least partially via inhibiting NFκB activation. This is the first in vivo demonstration that MgCl2 decreases cytokine release in arthritis, prompting reduction of inflammation and pain relief.
Neuropathological hints from CSF and serum biomarkers in corticobasal syndrome (CBS): a systematic review
Authors: Remoli Giulia , Schilke Edoardo Dalmato , Magi Andrea , Ancidoni Antonio , Negro Giulia , Da Re Fulvio , Frigo Maura , Giordano Martina , Vanacore Nicola , Canevelli Marco , Ferrarese Carlo , Tremolizzo Lucio , Appollonio Ildebrando 
Published: January 2024

AbstractCorticobasal syndrome (CBS) is a clinical syndrome determined by various underlying neurodegenerative disorders requiring a pathological assessment for a definitive diagnosis. A literature review was performed following the methodology described in the Cochrane Handbook for Systematic Reviews to investigate the additional value of traditional and cutting-edge cerebrospinal fluid (CSF) and serum/plasma biomarkers in profiling CBS. Four databases were screened applying predefined inclusion criteria: (1) recruiting patients with CBS; (2) analyzing CSF/plasma biomarkers in CBS. The review highlights the potential role of the association of fluid biomarkers in diagnostic workup of CBS, since they may contribute to a more accurate diagnosis and patient selection for future disease-modifying agent; for example, future trial designs should consider baseline CSF Neurofilament Light Chains (NfL) or progranulin dosage to stratify treatment arms according to neuropathological substrates, and serum NfL dosage might be used to monitor the evolution of CBS. In this scenario, prospective cohort studies, starting with neurological examination and neuropsychological tests, should be considered to assess the correlations of clinical profiles and various biomarkers.
Revalidating a measurement instrument of spatial thinking ability for junior and high school students
Authors: Thayaseelan Kannaki , Zhai Yanfang , Li Siqi , Liu Xiufeng 
Published: January 2024

AbstractSpatial thinking is a set of cognitive abilities that enable people to organize, reason about, and mentally manipulate both real and imagined spaces. One of the available measurement instruments is the Spatial Thinking Ability Test (STAT). Given the critical need for spatial thinking ability measurement for junior and high school students, and the popularity of STAT to measure spatial thinking ability, revalidation of STAT is necessary as STAT was developed primarily for university students and validation of the original STAT was based on the classical test theory from which the findings are notoriously sample dependent. We used Rasch modeling to revalidate STAT as it allows parameters to be mutually independent and measures to be interval. The sample included 1340 junior and high school students. Item fit statistics, Item Characteristics Curves, unidimensionality test, and the Wright map provided evidence for the construct validity of STAT measures. The reliability of the instrument was moderate. Wald test for item measure invariance of individual items showed that among sixteen items seven items were variant in measures. The Anderson LR test indicates that the Rasch difficulty measures of STAT were not adequate for invariance. There was no DIF between two subsamples based on gender, suggesting fairness of the instrument in terms of gender. The above results suggest that STAT possesses certain degrees of validity, reliability, and fairness, although there is still room for further improvement.
Pan-cancer analysis identified IGF2BP2 as a potential prognostic biomarker for multiple tumor types
Authors: Zhou Hong-Lu , Chen Dan-Dan , Li Xiu-Ling 
Published: January 2024

Abstract
Background
Insulin-like growth factor 2 (IGF2) mRNA-binding proteins 2 (IGF2BP2/IMP2), an RNA-binding protein encoded by the IGF2BP2 gene, exerts its influence across diverse pathological pathways. While accumulating evidence underscores the potential significance of IGF2BP2 in the tumorigenesis of specific cancers, a comprehensive pan-cancer investigation into its role remains absent.

Methods
Consequently, we conducted an exhaustive exploration employing a multitude of databases to elucidate the plausible oncogenic implications of IGF2BP2. This encompassed a comprehensive scrutiny of its expression profiles, prognostic implications, association with cancer-associated fibroblast infiltration, biological functionality in distinct tumor contexts, and plausible correlations with drug sensitivities.

Results
Our findings showed that IGF2BP2 was highly expressed in some types of cancers, but presented at low levels in several cancer types. Furthermore, the role of IGF2BP2 in predicting prognosis exhibited a dichotomous interplay across varied cancer types. Remarkably, observations unveiled the cancer-associated fibroblast infiltration within specific tumors, notably encompassing breast invasive carcinoma of the luminal A subtype, kidney renal clear cell carcinoma, ovarian serous cystadenocarcinoma, pheochromocytoma and paraganglioma, and prostate adenocarcinoma, and thymoma. Intriguingly, gene enrichment analyses spotlighted the co-expression of IGF2BP2 with genes implicated in pivotal biological processes, including DNA replication and recombinational repair.

Conclusion
Our investigation intricately unveils the potential of IGF2BP2 as a versatile prognostic biomarker across diverse tumor categories. This study bridges existing knowledge gaps and augments the understanding of IGF2BP2’s intricate involvement in tumorigenesis, underscoring its significance as a prospective avenue for therapeutic intervention.
A feasibility study of provider-level implementation strategies to improve access to colorectal cancer screening for patients with schizophrenia: ACCESS2 (N-EQUITY 2104) trial
Authors: Fujiwara Masaki , Yamada Yuto , Etoh Tsuyoshi , Shimazu Taichi , Kodama Masafumi , Yamada Norihito , Asada Takahiro , Horii Shigeo , Kobayashi Takafumi , Hayashi Teruo , Ehara Yoshitaka , Fukuda Kenji , Harada Keita , Fujimori Maiko , Odawara Miyuki , Takahashi Hirokazu , Hinotsu Shiro , Nakaya Naoki , Uchitomi Yosuke , Inagaki Masatoshi 
Published: January 2024

Abstract
Background
People with schizophrenia have a lower colorectal screening rate than the general population. A previous study reported an intervention using case management to encourage colorectal cancer screening for patients with schizophrenia in psychiatric outpatient settings. In this feasibility study, we developed provider-level implementation strategies and evaluated the feasibility of conducting a definitive trial in terms of the penetration of the intervention assessed at the patient level. Additionally, we examined the fidelity of strategies to implement the intervention at the provider level in a routine clinical psychiatric setting.

Methods
This was a multicenter, single-arm feasibility study with medical staff at psychiatric hospitals in Japan. The provider-level implementation strategies developed in this study included three key elements (organizing an implementation team appointed by the facility director, interactive assistance using a clear guide that outlines who in the hospital should do what, and developing accessible educational materials) to overcome major barriers to implementation of the intervention and four additional elements (progress monitoring, joint meetings and information sharing among participating sites, adaptation of encouragement methods to specific contexts, and education of on-site staff), with reference to the elements identified in the Expert Recommendations for Implementing Change (ERIC). The feasibility of the strategies was evaluated by the proportion of patients who were eligible for encouragement (patients with schizophrenia aged 40, 50, or 60) who received encouragement. We set the goal of providing encouragement to at least 40% of eligible patients at each site.

Results
Two public and four private psychiatric hospitals in Okayama and Shimane prefectures participated in this study. Regarding fidelity, all elements of the strategies were conducted as planned. Following the procedures in the guide, each team prepared and provided encouragement according to their own facility and region. Penetration, defined as the proportion of eligible patients who received encouragement, ranged from 33.3 to 100%; five of the six facilities achieved the target proportion.

Conclusions
The provider-level implementation strategies to implement encouragement were feasible in terms of penetration of the intervention assessed at the patient level. The results support the feasibility of proceeding with a future definitive trial of these strategies.

Trial registration
jRCT, jRCT1060220026. Registered on 06/04/2022.
Solubility enhancing lipid-based vehicles for artemether and lumefantrine destined for the possible treatment of induced malaria and inflammation: in vitro and in vivo evaluations
Authors: Ugorji Onyinyechi Lydia , Onyishi Ikechukwu Virgilius , Onwodi Julie Ngozichukwuka , Adeyeye Christiania Moji , Ukachukwu Uzochukwu Gospel , Obitte Nicholas Chinedu 
Published: January 2024

Abstract
Background
The lipid self-emulsifying system has been advanced as a promising delivery vehicle for improving the solubility and bioavailability of artemether and lumefantrine. However, the observed kinetic instability (propensity of lumefantrine to rapid crystallisation from nano-scale droplets) in aqueous acid has impelled some researchers to incorporate surfactants/solubilizers in the dissolution medium prior to dissolution studies. Thus, in our present work, we sought to prepare micro/large nano-scale (> 100 nm) and yet kinetically stable lumefantrine lipid self-emulsifying system (that would not require an external drug dissolution enhancing agent in the dissolution medium) and palm kernel oil-based 100 nm kinetically stable artemether lipid self-emulsifying system with rapid emulsification time. COVID-19 and Plasmodium falciparum-infected Africans with previous long exposure to malaria have manifested attenuated inflammatory cytokines more than malaria-naive patients. Therefore, the ingestion of artemether-lumefantrine with enhanced solubility may further promote blunting of cytokines. Therefore, this work was aimed at preparing (< 100 nm) stable artemether and aqueous acid-stable micro/large nano-scale (> 100 nm) lumefantrine lipid self-emulsifying system destined for improved antimalarial and anti-inflammatory activities.

Results
The droplet sizes of all the liquid artemether and lumefantrine formulations were between 8.95–39.88 and 1018–4195 nm, respectively. The loading efficiency for all the formulations was, between 72.91 ± 2.89 and 100.00 ± 0.29%. All the artemether and lumefantrine batches emulsified within the range of 3.90 ± 0.69 to 12.26 ± 0.69 s. Stable and transparent emulsions were formed on aqueous dilution to 1000 ml. The percentage drug released for artemether and lumefantrine ranged from 76.25 ± 2.98 to 99.22 ± 1.61%. The solid lipid self-emulsifying systems produced, had fair and passable flow properties. Differential scanning calorimetry revealed that the solid artemether and lumefantrine lipid self-emulsifying system were amorphous. Solidification with Neusilin FH2 or surfactant replacement with Kolliphor EL and Kollidon VA 64 fine prevented micro-or large nano-scale lumefantrine lipid self-emulsifying system from crystallisation in aqueous acid (pH 1.2). Higher antimalarial activity and remarkable anti-inflammatory effects (P < 0.05) favoured the lipid self-emulsifying formulations.

Conclusion
Optimal in vitro and in vivo results (enhanced antimalarial and anti-inflammatory activities) were obtained with kinetically stable lumefantrine micro/large nano-scale droplets and kinetically stable palm kernel oil-based (< 50 nm) artemether lipid self-emulsifying system droplets.
Use of agro-industrial bio-waste for the growth and production of a previously isolated Bacillus thuringiensis strain
Authors: dos Santos Hister M. M. , de S. Varize Camila , Valença Camilla A. S. , Dossi Fábio C. A. , de Aragão Batista Marcus V. , Fernandes Roberta P. M. , Severino Patricia , Souto Eliana B. , Dolabella Silvio S. , da C. Mendonça Marcelo , Jain Sona 
Published: January 2024

Abstract
Background
Bacillus thuringiensis (Bt) is a widely used biopesticide. The bioinsecticide based on Bt is obtained by fermentation, but the substrates currently used for its production constitute ingredients of high commercial value. In this context, the use of agro-industrial residues as substrates is an alternative to make the fermentation process viable on a large scale, in addition to minimizing environmental problems and contributing to the destination of these residues for biotechnological purposes.

Results
In the first part of this study, a previously isolated spore forming soil bacteria (Bv5) harboring and expressing a novel cry 8A gene was confirmed as B. thuringiensis based on its morphological characteristics, Gram staining, scanning electron microscopy (SEM) and genome sequencing. Bv5 was established as a Gram-positive spore forming bacteria with ellipsoidal spores and small round toxins. Bv5 genome comprised of the 5.30 Mb chromosome and two megaplasmids of 450 kb and 261 kb, respectively, with cry 8A gene located on the smallest megaplasmid. In the second part of the study, the physiological profile of the Bv5 strain during fermentation in different agro-industrial biowastes (cassava wastewater, orange pulp wash and whey) was analyzed. The fermentation experiment was divided into two stages. In the first stage, the agro-industrial waste with or without salts with the best results for biomass, spores and proteins production was selected. In the second stage, the effect of the selected medium in original and diluted form with the C:N balance was evaluated, in two different fermentation times (72 h and 96 h). Pulp wash enriched with salts was selected as the most suitable medium for the growth of Bv5 strain in the first stage. In the second stage pulp wash (without dilution) with the addition of salts, and with nitrogen supplementation, was considered the best for cell growth, spore and toxin production by Bv5.

Conclusions
To conclude, our study provide a new alternative for bio-waste from the orange juice industry, as well as potential culture medium for the Bt commercial scale production.
Using radiomics for predicting the HPV status of oropharyngeal tumors
Authors: Sarac Kubra , Guvenis Albert 
Published: January 2024

AbstractKnowing human papillomavirus (HPV) status has important consequences for treatment selection in oropharyngeal cancer. The gold standard is to perform a biopsy. The objective of this paper is to develop a new computed tomography (CT) radiomics-based non-invasive solution to HPV status determination and investigate if and how it can be a viable and accurate complementary technique. Two hundred thirty-eight patients’ CT scans were normalized and resampled. One thousand one hundred forty-two radiomics features were obtained from the segmented CT scans. The number of radiomic attributes was decreased by applying correlation coefficient analysis, backward elimination, and random forest feature importance analysis. Random over-sampling (ROSE) resampling algorithm was performed on the training set for data balancing, and as a result, 161 samples were obtained for each of the HPV classes of the training set. A random forest (RF) classification algorithm was used as a prediction model using five-fold cross-validation (CV). Model effectiveness was evaluated on the unused 20% of the imbalanced data. The applicability of the model was investigated based on previous research and error rates reported for biopsy procedures. The HPV status was determined with an accuracy of 91% (95% CI 83–99) and an area under the curve (AUC) of 0.77 (95% CI 65–89) on the test data. The error rates were comparable to those encountered in biopsy. As a conclusion, radiomics has the potential to predict HPV status with accuracy levels that are comparable to biopsy. Future work is needed to improve standardization, interpretability, robustness, and reproducibility before clinical translation.
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
Authors: Bedrosian Isabelle , Somerfield Mark R. , Achatz Maria Isabel , Boughey Judy C. , Curigliano Giuseppe , Friedman Sue , Kohlmann Wendy K. , Kurian Allison W. , Laronga Christine , Lynce Filipa , Norquist Barbara S. , Plichta Jennifer K. , Rodriguez Patricia , Shah Payal D. , Tischkowitz Marc , Wood Marie , Yadav Siddhartha , Yao Katherine , Robson Mark E. 
Published: January 2024

PURPOSE To develop recommendations for germline mutation testing for patients with breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. RESULTS Forty-seven articles met eligibility criteria for the germline mutation testing recommendations; 18 for the genetic counseling recommendations. RECOMMENDATIONS BRCA1/ 2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and select patients >65 years based on personal history, family history, ancestry, or eligibility for poly(ADP-ribose) polymerase (PARP) inhibitor therapy. All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/ 2 testing, regardless of family history. BRCA1/ 2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralateral breast. For patients with prior history of breast cancer and without active disease, testing should be offered to patients diagnosed ≤65 years and selectively in patients diagnosed after 65 years, if it will inform personal and family risk. Testing for high-penetrance cancer susceptibility genes beyond BRCA1/ 2 should be offered to those with supportive family histories; testing for moderate-penetrance genes may be offered if necessary to inform personal and family cancer risk. Patients should be provided enough pretest information for informed consent; those with pathogenic variants should receive individualized post-test counseling. Variants of uncertain significance should not impact management, and patients with such variants should be followed for reclassification. Referral to providers experienced in clinical cancer genetics may help facilitate patient selection and interpretation of expanded testing, and provide counseling of individuals without pathogenic germline variants but with significant family history. Additional information is available at www.asco.org/breast-cancer-guidelines .
Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT
Authors: Ramchand Sabashini K , Hoermann Rudolf , White Shane , Yeo Belinda , Francis Prudence A , Xu Cecilia L H , Zajac Jeffrey D , Seeman Ego , Grossmann Mathis 
Published: January 2024

Abstract

Context
Menopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified in premenopausal women receiving estradiol suppression for breast cancer. Denosumab offsets deleterious skeletal effects of estradiol suppression and has been reported to have effects on body composition and metabolic parameters in preclinical and observational studies, but evidence from double-blind randomized controlled trials is limited.

Objective
To assess the effect of denosumab on body composition and metabolic parameters.

Methods
In a prespecified secondary analysis of a 12-month randomized, double-blind, placebo-controlled trial, 68 premenopausal women with breast cancer initiating ovarian function suppression and aromatase inhibition were randomized to denosumab 60-mg or placebo administered at baseline and 6 months. Outcome measures were total and regional fat and lean mass (DXA), body mass index (BMI), waist and hip circumference, fasting glucose, HOMA-IR, and lipid profile. Using a mixed model, between-group mean adjusted differences over time are reported.

Results
Over 12 months, relative to placebo, android and gynoid fat mass decreased in the denosumab group (−266 g [95% CI −453 to −79], P = .02, and −452 g [−783 to −122], P = .03, respectively). Total fat mass and waist circumference were lower in the denosumab group but not significantly (−1792 g [−3346 to −240], P = .08 and (− 3.77 cm [−6.76 to −0.79], P = .06, respectively). No significant treatment effects were detected in lean mass, BMI, hip circumference, fasting glucose, HOMA-IR, or lipid profile.

Conclusion
In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.
Novel Application of Microdosing Glucagon for Hypoglycemia After Total Pancreatectomy and Autologous Islet Transplant
Authors: Rafi Ebne , Lewis Claudia , Hatipoglu Betul 
Published: January 2024

Abstract
Total pancreatectomy and autologous islet transplantation (TPAIT) is a procedure to ameliorate dysglycemia associated with post-pancreatectomy. Patients who undergo TPAIT are at risk of developing hypoglycemia postoperatively. The current literature suggests that hypoglycemia may be due to a glucagon-deficiency state. To date, there is minimal literature available that explores treatment options to minimize hypoglycemia in these patients. In this case, a 29-year-old female patient was administered a microdosing glucagon protocol post TPAIT and experienced improvements in hypoglycemia. We describe the dosing regimen of the protocol and provide continuous glucose monitoring data to support our findings. This case adds to the limited evidence on effective treatment options for these rare patients. To our knowledge, this is the first application of a microdosing glucagon protocol to treat hypoglycemia associated with TPAIT.